Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.

@article{Kohno2005ZoledronicAS,
  title={Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.},
  author={Norio Kohno and Kenjiro Aogi and Hironobu Minami and Seigo Nakamura and Taro Asaga and Yuichi Iino and Toru Watanabe and Carsten Goessl and Yasuo Ohashi and Shigemitsu Takashima},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 15},
  pages={3314-21}
}
PURPOSE To investigate the efficacy and safety of zoledronic acid for the treatment of bone metastases from breast cancer. PATIENTS AND METHODS Women with bone metastases (N = 228) were randomly assigned to receive 4 mg zoledronic acid (n = 114) or placebo (n = 114) via 15-minute infusions every 4 weeks for 1 year. The primary efficacy end point was the skeletal-related event (SRE) rate ratio between treatment groups. An SRE was defined as pathologic fracture, spinal cord compression, and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 183 extracted citations

Similar Papers

Loading similar papers…